E6011

Phase 2Small molecule

Eisai

E6011 is one of 66 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Primary Biliary CholangitisActive, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Primary Biliary CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Rituxan

61 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Actos

Takeda

Preclinical

2 7

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 8

E6011

Eisai

Phase 2

3 9

Rituxan

Pfizer

Preclinical

7 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis

Completed· Eisai logo

Eisai·Phase 1/2·NCT02196558·53 enrolled

A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

Completed· Eisai logo

Eisai·Phase 2·NCT02960490·66 enrolled

A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

Completed· Eisai logo

Eisai·Phase 2·NCT02960438·273 enrolled

Crohn's Disease2 trials

A Study of E6011 in Participants With Active Crohn's Disease

Completed·EEA Pharma Co., Ltd.·Phase 2·NCT03733314·25 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

Withdrawn· Eisai logo

Eisai·Phase 1·NCT02249078

Single Dose1 trial

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Completed· Eisai logo

Eisai·Phase 1·NCT01731275·64 enrolled

Primary Biliary Cholangitis1 trial

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Terminated·EEA Pharma Co., Ltd.·Phase 2·NCT03092765·29 enrolled

Phase 11 trial

A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects

Completed· Eisai logo

Eisai·Phase 1·NCT02146261·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for E6011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E6011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E6011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eisai

E6011

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Crohn's Disease2 trials

Single Dose1 trial

Primary Biliary Cholangitis1 trial

Phase 11 trial

References

Drug Info

Quick Facts

Related News